Gugler R, von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1980;5:67-83. https://doi.org/10.2165/00003088-198005010-00002

Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurol Scand 2006;114(1):1-7. https://doi.org/10.1111/j.1600-0404.2006.00655.x

Coulter DL, Allen RJ. Hyperammonemia with valproic acid therapy. J Pediatr 1981;99(2):317-9. https://doi.org/10.1016/S0022-3476(81)80489-1

Kowalski PC, Dowben JS, Keltner NL. Ammonium: the deadly toxin you don't want to miss when using mood stabilizers. Perspect Psychiatr Care 2013;49(4):221-5. https://doi.org/10.1111/ppc.12040

Yamamoto Y, Takahashi Y, Suzuki E, Mishima N, Inoue K, Itoh K, et al. Risk factors for Hyperammonemia associated with valproic acid therapy in adult epilepsy patients. Epilepsy Res 2012;101:202-9. https://doi.org/10.1016/j.eplepsyres.2012.04.001

Yamamoto Y, Takahashi Y, Imai K, Mishima N, Yazawa R, Inoue K, et al. Risk factors for Hyperammonemia in pediatric patients with epilepsy. Epilepsia 2013;54:983-89. https://doi.org/10.1111/epi.12125

Hafeez Q- ul-A. Interaction between Meropenem and Valproate: Not to overlook. Int J Endor Health Sci Res 2016;4(1):27-1. https://doi.org/10.29052/IJEHSR.v4.i1.2016.27-31

Iqbal K, Kummamuru H, Dasari N, Koritala T, Jain NK, Deepika K, et al. A case of valproic-acid induced hyperammonemic encephalopathy. Cureus 2021;13(12):e20380. https://doi.org/10.7759/cureus.20380

Amanat S, Shahbaz N, Hassan Y. Valproic acid induced hyperammonaemic encephalopathy. J Pak Med Assoc 2013;63(1):72-5.

Baddour E, Tewksbury A, Stauner N. Valproic acid–induced Hyperammonemia: Incidence, clinical significance, and treatment management. Ment Health Clin 2018;8(2):73-7. https://doi.org/10.9740/mhc.2018.03.073

Tseng YL, Huang CR, Lin CH, Lu YT, Lu CH, Chen NC, et al. Risk factors of Hyperammonemia in patients with epilepsy under valproic acid therapy. Medicine (Baltimore) 2014;93(11):e66. https://doi.org/10.1097/MD.0000000000000066

Lewis C, Tesar GE, Dale R. Valproate-induced hyperammonemic encephalopathy in general hospital patients with one or more psychiatric disorders. Psychosomatics 2017;58(4):415–20. https://doi.org/10.1016/j.psym.2017.02.003

McMorris T, Chu A, Vu L, Bernardini A. Hyperammonemia in patients receiving valproic acid in the hospital setting: a retrospective review. Ment Health Clin 2021;11(4):243-7. https://doi.org/10.9740/mhc.2021.07.243

Kumar A, Suri A, Sharma BS. Severe valproate induced hyperammonemic encephalopathy successfully managed with peritoneal dialysis. Indian J Crit Care Med 2014;18(7):461-3. https://doi.org/10.4103/0972-5229.136076

Habhab SF, Ulvin LB, Taubøll E, Svalheim S, Olsen KB, Horn MA, et al. Influence of valproate-induced Hyperammonemia on treatment decision in an adult status epilepticus cohort. Epilepsy Behav 2020;111:107193. https://doi.org/10.1016/j.yebeh.2020.107193